<p>Discovering Biomarkers in Peritoneal Metastasis of Gastric Cancer by Metabolomics</p>

Abstract

Background and Objective: Metabolomics has recently been applied in the field of oncology. In this study, we aimed to use metabolomics to explore biomarkers in peritoneal metastasis of gastric cancer. Methods: Peritoneal lavage fluid (PLF) of 65 gastric cancer patients and related clinical data were collected from the First Hospital of Jilin University. The metabolic components were identified by liquid chromatography-mass spectrometry (LC-MS). Total ion current (TIC) spectra, principal component analysis (PCA), and the Student's t-test were used to identify differential metabolites in PLF. A support vector machine (SVM) was used to screen the differential metabolites in PLF with a weight of 100%. Cluster analysis was used to evaluate the similarity between samples. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic ability of the metabolites. Univariate and multivariate logistic regression analyses were used to identify potential risk factors for peritoneal metastasis of gastric cancer. Results: We found the differential levels of PLF metabolites by LC-MS, TIC spectra, PCA and the t-test. Cluster analysis showed the co-occurrence of metabolites in the peritoneal metastasis group (p<0.05). ROC analysis showed the diagnostic ability of metabolites (p<0.05). Univariate and multivariate logistic regression analyses showed the potential independent risk factors for peritoneal metastasis in gastric cancer patients (p<0.05). Conclusion: Through the statistical analysis of metabolomics, we found that TG (54:2

UHPLC-ESI-MS/MS Quantification of Relevant Substrates and Metabolites of the Kynurenine Pathway Present in Serum and Peritoneal Fluid from Gastric Cancer Patients—Method Development and Validation

“…While most studies focus on the metabolomics in blood, there is a lack of data available on the validated procedure for LC-MS/MS quantification of KP metabolites in the peritoneal fluid, especially in the context of gastric cancer. Pan et al screened samples of peritoneal fluid from GC patients to identify differential metabolites, but no quantitative analysis of kynurenines has been performed [43].…”

Discovering Biomarkers in Gastric Cancer by Urine Metabolomics

“…The LC-MS examination was performed as previously reported [13]. Briefly, the mobile phase was ultrasonicated in a numerically controlled ultrasonic cleaner to exhaust the gas before the LC-MS examination.…”

Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis

“…The peritoneal ecosystem is highly complex, including distinct heterogeneous immune cell populations 12 , 13 . Both peritoneal exfoliated tumor cells (PETCs) and immune cells in the abdominal cavity undergo diverse changes during GCPM development, and anti-tumor therapy might lead to a therapy-induced evolution of GCPM cells, in turn affecting their sensitivity to therapy 14 – 16 . Comprehensive dissection of the characteristics of peritoneal infiltrating immune cells and PETCs with single-cell resolution is necessary to better understand the underlying molecular mechanisms of GCPM and provide insights into future therapy strategies.…”